ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Aprea is advancing APR-1051 as monotherapy in cancers with Cyclin E over-expression, as well as other biomarkers that may predict sensitivity to WEE1 inhibition. Cancers over-expressing Cyclin E ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...

Learn more about whether Blueprint Medicines Corporation or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock. Syros ...

Events across the Metroplex have been canceled or delayed as hail and strong winds are expected Saturday morning.

Cyclacel Pharmaceuticals, Inc.’s CYCC share price has dipped by 15.89%, which has investors questioning if this is right time ...

Equities research analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report issued on Monday. The brokerage set a “sell” rating on ...

The authors provide convincing evidence showing that this mechanism is triggered in pathological states in which cyclin D levels are elevated (e.g., cancer). Overall, this study holds a promise to ...

For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge. New CU Boulder research, published in the ...

E) Schematic representation of candidate CDK phosphorylation sites in GTSE1, as indicated by the PhosphoSitePlus database 24. F) HEK293T cells were transiently transfected with the indicated HA-GTSE1 ...